Introduction
Tumorigenesis is a complex process that is driven by a number of genetic and epigenetic alterations, which often result in aberrant gene expression (1) (2) (3) .
Mutations are generally considered to be the primary drivers of tumorigenesis (4, 5) . However, dysregulation of epigenetic regulatory mechanisms also contributes to malignant transformation. Methylation of cytosine at CpG sequences in DNA leading to the formation of 5-methylcytosine (5mC) is one of the most stable and most widely studied epigenetic modifications (6) . In most human tumors, widespread hypermethylation of CpG-rich sequences (CpG islands) is observed along with genome-wide DNA hypomethylation (1, (7) (8) (9) (10) (11) (12) (13) (14) . DNA hypermethylation in cancer is not a random event; it commonly affects specific gene classes and is seen most frequently at targets of the Polycomb repression complex (15) (16) (17) (18) including numerous homeobox genes (19, 20) . However, many of the genes marked by Polycomb in normal tissues and cell types, for example embryonic stem cells, are expressed at very low levels in these cells (21, 22) . The acquisition of the more permanent silencing mark, 5mC, at the promoters of Polycomb target genes does not fundamentally change their expression levels although plasticity of expression will be reduced. For these reasons, it has remained unclear whether methylation of Polycomb target genes plays an essential role in tumor promotion and is in fact a tumor-driving event (23) .
Recently, genome sequencing has identified a high frequency of mutations in epigenetic regulatory factors or chromatin structural elements in human malignancies (24, 25) . However, technical limitations have made it difficult to directly examine chromatin changes in normal and malignant tissues, with most studies being limited to in vitro cell culture models. In order to determine the role of histone modifications in targeting DNA methylation and in altering gene expression patterns in human primary tumors, we have conducted the first comprehensive analysis of frozen tissues from colorectal cancer (CRC) patients focusing on two histone methylation marks, the activating histone H3 lysine 4 trimethylation (H3K4me3) and the repressive histone H3 lysine 27 trimethylation (H3K27me3), which are thought to be critical for gene regulation. 4 We found that genes carrying both histone modifications (bivalent genes) in normal tissue are characterized by substantial variability and undergo reorganization of these modifications in colorectal cancer leading to activation of cancer-promoting genes as one important outcome that can confer tumor-driving properties onto an emerging malignant cell population.
Material and Methods

Human tissue samples
Human Duke's stage II colon cancers and matching normal mucosa were obtained from the Cooperative Human Tissue Network (CHTN).
Gene expression analysis
Total RNA from patient samples was purified by using the mirVana kit (Ambion, Life Technologies). For whole genome expression analysis, GeneChip® Human Gene 2.0 ST arrays (Affymetrix) were used. Validation of gene expression changes by real-time reverse transcription-PCR was performed as described previously (18) . All expression data were normalized to GAPDH in the same sample.
Analysis of 5mC patterns
For analysis of genomic 5mC patterns, the methylated CpG island recovery assay (MIRA) was used as described previously (26) . After genome amplification, the methylated DNA fraction was hybridized versus input DNA on human CpG island/promoter microarrays (NimbleGen). The observed MIRA patterns for single CpG islands were validated by combined bisulfite restriction analysis (COBRA) as described previously (18) . Primer sequences are available upon request. 
Chromatin immunoprecipitation
For chromatin immunoprecipitation, frozen tissues were crushed with a plastic pestle in ice-cold phosphate-buffered saline (PBS) and fixed for 10 min at room temperature in 1% formaldehyde. Chromatin immunoprecipitation and genome amplification protocols were performed as described previously (26) . The following antibodies were used: anti-H3K4me3 (39159, Active Motif), and antiH3K27me3 (07-449, Millipore). For obtaining the H3K4me3 profile, H3K4me3 antibodies were pre-blocked with an H3K9me3 peptide (Abcam) to remove minor cross-reactivity of this antibody. After genome amplification, immunoprecipitated DNA was hybridized versus input DNA on human CpG island/promoter microarrays (NimbleGen).
For sequential chromatin immunoprecipitation (ReChIP), the first immunoprecipitation was performed as described above except for the elution step which was performed with SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1, 1x cOmplete Protease Inhibitor Cocktail, Roche Applied Science) for 10 min at 68°C on a shaker at 1000 rpm. After removal of beads, the samples were diluted with 1:10 ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.1, 167 mM NaCl, 22 μg/ml BSA, 1x cOmplete Protease Inhibitor Cocktail) and incubated with protein A/G PLUSagarose (sc-2003, Santa Cruz Biotechnology), pre-blocked with BSA and herring sperm DNA, for 30 min at 4°C. After removal of beads, chromatin was incubated with anti-H3K4me3 (39159, Active Motif), anti-H3K27me3 (17-622, Millipore) or IgG (17-622, Millipore) antibodies overnight at 4°C followed by further incubation with protein A/G PLUS-agarose. Beads were washed once with low salt immune complex wash buffer (0.1% SDS, 1%Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM NaCl, 1x cOmplete Protease Inhibitor Cocktail) and twice with high salt immune complex wash buffer (0.1% SDS, 1%Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 500 mM NaCl, 1x cOmplete Protease Inhibitor Cocktail). Chromatin was eluted with SDS lysis buffer for 10 min at 68°C on a shaker at 1000 rpm and crosslinks were reversed in presence of 300 mM NaCl at 6 65°C overnight. Primer sequences for qPCR of individual genes are available upon request. Analysis was done with tissues from patient #14. Results are for triplicate experiments (+/-S.D.).
Bioinformatics analysis
All analysis was performed using R statistical language, except for gene ontology analysis, which was performed using DAVID annotation tools and Ingenuity Pathway Analysis. The heat-maps were generated with Cluster v3.0 and Java Treeview v2.0. Refseq genes were downloaded from the UCSC hg18 annotation database. Promoter was defined as -1.4 kb to + 0.6 kb relative to the transcription start site (TSS). For heat-maps with epigenetic marks, only genes with gene body length greater than 2 kb were included. Genes that were differentially expressed during colorectal cancer formation were identified as those with a log2 fold change >1. Probes were considered positive if their normalized log2 ratios were above 1.5-fold. Peaks in each sample were defined as four or more consecutive positive probes with either one or no gaps. A promoter was defined as bivalent if it contained overlapping H3K4me3 and H3K27me3 peaks at expanded promoter areas (-2.4 kb < TSS < 0.6 kb). Affymetrix expression array data were used to generate heat-maps as described previously (27) . All array data were deposited in the GEO database (accession number GSE47076). promoters (Fig. S1 ). In total, we analyzed eleven regions by bisulfite-based methods and observed that the two approaches yielded excellent correlation for all regions examined.
To judge the quality of chromatin immunoprecipitation (ChIP) conducted on the frozen tissues, we performed several bioinformatics comparisons of our ChIP data with DNA methylation and gene expression data obtained with the presumably more stable DNA or RNA material obtained from the same samples.
As shown in Figure S2 , ChIP patterns from frozen tissues are very reproducible between samples and provide remarkable consistency among independent ChIP analyses within the same tissue (R=0.89, p<0.0001) (Fig. S2A ). Our data revealed the well-established negative correlation (R=-0.6, p<0.0001) between 5mC and H3K4me3 at CpG islands (29, 30) (Fig. 1A) . Furthermore, changes of H3K4me3 at promoters occurring between tumors and matching normal tissues were strongly linked to transcriptional changes analyzed at the RNA level (Fig.   1C ). Genes gaining H3K4me3 at promoters were frequently activated in tumors and genes, which lost H3K4me3, were repressed. Genome-wide, DNA methylation changes at promoters also showed a strong negative correlation with H3K4me3 changes between tumors and matching normal tissues (Fig. 1B) .
Taken together, these data confirmed the reliability of our chromatin mapping approach using frozen tissue specimens.
Variability of H3K27me3
Analysis of H3K27me3-marked genomic regions showed many similarities between tumor and nonmalignant matching specimens (e.g., Fig. S2D and S3A).
However, in contrast to the generally more invariant H3K4me3 patterns, we observed a substantial degree of instability of the H3K27me3 mark when comparing normal and tumor samples ( Fig promoter and at the long HOXC9 isoform promoter (Fig. 2B ). Thus, a loss of H3K27me3 at distinct promoters can be involved in H3K4me3 accumulation or aberrant DNA methylation and can have a major impact on transcript isoform usage in colorectal tumors. In order to evaluate if these observations apply to the cancer epigenome as a whole, and to determine whether alterations of the H3K27me3 patterns reflect transcriptional changes, we used the heat-map approach for promoter regions and sorted genes by H3K27me3 changes (Fig.   2C,D) . We examined the 15% of genes that showed the greatest loss of H3K27me3 at promoters, and we additionally sorted these genes by H3K4me3 changes (Fig. 2C,D) . We found that H3K4me3 alterations within this group of genes negatively correlated with accumulation of aberrant DNA methylation at promoters. At the same time, accumulation of H3K4me3 at promoters, which lost H3K27me3 in tumors, was frequently associated with gene activation (Fig. 2D) .
Thus, at a genome-wide level, we confirmed the two different correlates of H3K27me3 loss in colorectal cancer, gain of 5mC, or gene activation.
Bivalent chromatin in ES cells and colonic mucosa
Bivalent (H3K4me3 and H3K27me3 containing) chromatin status is a key regulatory mechanism during embryonic stem (ES) cell maintenance and differentiation (31, 32) . We first asked to what extent bivalent promoter status is retained in human colonic mucosa versus ES cells. We found that the number of bivalent promoters varies between 3,414 and 3,967 within the normal colonic mucosal samples (Fig. S4A) . Approximately 50-60% of these bivalent promoters in normal colon are also bivalent in ES cells, whereas 40-50% of bivalent promoters are specific for colon. Gene ontology analysis using DAVID S4B ). Previously, aberrant DNA methylation in cancer has been linked to the bivalent state of promoters (15) . In order to further assess this correlation, we compared the bivalent promoter state in normal tissue to aberrant methylation in matching tumors (Fig. S5A ) and observed that genes with bivalent promoters comprise the vast majority of promoters with cancer-associated DNA methylation. Strikingly, the presence of H3K27me3 at promoters in normal colon epithelial tissue was associated with 90% of all hypermethylated sites (Fig. S5B) and approximately 70% of aberrantly methylated promoters had a bivalent state in normal colon tissue (Fig. S5A ).
Since the simultaneous presence of H3K4me3 and H3K27me3 at promoters might reflect different cell populations, we examined chromatin state at several candidate genes by sequential immunoprecipitation (Fig. 3A and Fig.   S4C ). These experiments confirmed presence of both histone marks on the same immunoprecipitated DNA fragments in normal mucosa.
Chromatin changes at bivalent promoters
We next evaluated all epigenetic changes that target bivalent promoters in colorectal cancer. We generated a heat map containing information for H3K27me3, H3K4me3 and 5mC changes occurring at promoters with bivalent status in all analyzed normal colonic mucosa samples ( Fig. 3B ; Table S1 ). We (Fig. 3C ). This observation suggests that the variability of chromatin at bivalent promoters can lead to two opposite outcomes, a gain or a loss of H3K27me3, and may result in gene repression according to both scenarios if 5mC is gained in the latter. A majority of promoters with aberrant DNA methylation in tumors was associated with a loss of H3K27me3 (Fig. S5D) .
This phenomenon, which has been referred to as 'Polycomb switching' (34), was true for promoters with and without bivalent state (Fig. S5C,D) .
Gene activation at bivalent promoters in cancer
Our study identified a novel and distinct group of promoters where a loss of H3K27me3 is associated with accumulation or retention of H3K4me3 in tumors but generally little or no change in DNA methylation levels ( Fig. 3B ; promoter group marked by a green bar). These promoters were associated with strong gene activation (Fig. 3C) . Analysis of the transcriptome of bivalent promoters revealed a very high transcriptional instability of bivalent genes in tumors.
Approximately 26-46% of bivalent promoters were affected by transcriptional alterations (at least two-fold) in each tumor (Fig. 3D) . We found that 15-20% of the bivalent genes undergo transcriptional activation in tumors (Fig. 3D) .
In order to further elucidate the potential functional impact of bivalent promoter activation on colorectal cancer progression, we performed a detailed analysis of genes that are bivalent or non-bivalent in colonic mucosa and become activated at least two-fold in at least two out of four analyzed tumors (Table S2) . Non-bivalent genes activated in tumors were enriched for genes important in mitotic progression including mitotic kinases, mitotic cyclins and kinesins and checkpoint proteins ( Fig. S6A ; Table S2 ). The activated bivalent genes were strongly associated with the colonic transcriptome and transcriptional activity in colorectal cancer (Fig 4A) . Importantly, this group of genes was strongly enriched with genes involved in transcriptional regulation and associated with early development (Fig. S6B ; Table S2 ). The genes that become repressed in tumors and carry a bivalent status in mucosa were strongly linked to brain development (Fig. S6C ) whereas repressed non-bivalent genes did not show any functional categories with major enrichment (data not shown). Significantly, the non-bivalent genes did not show any enrichment for transcription factors (Table   S2 ), neither for activation nor for repression gene groups, suggesting that the enrichment of mitotic proteins in the non-bivalent group could be downstream of crucial regulators (e.g. cyclin D) encoded by the activated bivalent genes.
According to Ingenuity pathway analysis (www.ingenuity.com), the group of genes, which become activated in cancer and are bivalent in mucosa, was strongly enriched with genes associated with cancer as a disease (Fig. 4B) and with important aspects of the transformed phenotype (Table S3 ). For example, one of the main regulators of the epithelial to mesenchymal transition (EMT), SNAI2 was activated together with a loss of bivalent status in tumor tissues (Table S3) . This group of genes contains many genes encoding transcription factors and genes associated with cellular growth and proliferation such as the oncogene cyclin D1 (CCND1), ribonucleotide reductase (RRM2) and MKi67, genes associated with cell adhesion and invasion including claudin1 (CLDN1) and EPCAM and other genes strongly implicated in cancer such as COX2/PTGS2 and the MET oncogene ( Fig. 4D ; Table 1; Table S3 ; Fig. S6D ).
Three crypt stem cell markers, ASCL2, LGR5 and SOX9 (35) (36) (37) belong to the group of most frequently activated genes (in all tumors) with bivalent promoters in normal colonic epithelium (Fig. 4C,D ; Table 1; Table S3 ). This fact was also confirmed for LGR5 in 11 sample pairs by Q-RT-PCR (Fig. 4C) . activated genes showed enrichment for SOX9 and FOXQ1 binding sites (Fig.   S6E) . Interestingly, the genes coding for both transcription factors were activated due to loss of H3K27me3 in all tumors. In addition, two other intestinal stem cell signature genes, OLFM4 and EPHB3 were activated together with a loss of the H3K27me3 mark in CRC (Fig. 4D) . It is remarkable that the well-known proliferation marker, MKI67 (Ki67) and cancer stem cell markers such as Prominin 1 (CD133) and ALCAM (CD166) also became activated together with a loss of bivalent state in tumors ( Table 1, Table S3 ). These data suggest that loss of the bivalent state accompanied by activation of critical cell cycle drivers and tumor-promoting genes is a general and pervasive mechanism in colorectal cancer.
In order to evaluate the possibility that the apparent loss of H3K27me3 in tumors reflects an intestinal stem cell origin and presence of H3K27me3 in mucosa reflects a differentiation process in which this mark is acquired at promoters of stem cell genes, we determined if cancer-associated transcriptional changes in tumors carry primarily a gene expression signature indicative of cells at the crypt base where such stem cells reside. We used previously published expression profiling of human crypt top versus bottom samples (38) . From 3157 crypt bottom-specific genes, of which 306 genes carry a bivalent status in normal mucosa, we found only 26 crypt bottom genes including LGR5, ASCL2, MKi67 and CLDN1 to be activated in all tumors and bivalent in mucosa. At the same time, very few genes (ten) out of 2865 crypt top-specific genes, of which 251 genes carry bivalent character in mucosa, were repressed in all tumors and were bivalent in mucosa (Fig. S6F) . These data clearly suggest that the tumors we analyzed do not express a predominant stem cell-like phenotype. Analysis of genes, which are not associated with crypt top or bottom according to Kosinski and colleagues (38) , have bivalent status in mucosa and are activated in all tumors, revealed a strong association of these genes with cancer and epithelial neoplasia (Table S4 ). This fact suggests that this group of genes may play an important role in cancer development. We then tested if activation of bivalent genes may occur at an early stage of colorectal cancer progression. Based on publically available gene expression profiles of 32 human adenomas and matching mucosa (39), we evaluated if bivalent genes, which become activated in all tumors, undergo transcriptional changes in colorectal adenomas. Bivalent genes were activated slightly preferentially over non-bivalent genes in adenomas (18% versus 15%). However, the majority (54%) of bivalent genes activated in stage II CRC were also activated in adenoma. Among the activated genes were stem cell markers including LGR5, SOX9 and ASCL2 and proliferation-associated genes such as MKI67 and RRM2 (Fig. 4E ).
Transcriptional alterations of bivalent genes in inflamed mucosa
Chronic inflammation is a strong risk factor for cancer development (40) . Similar to colon cancer, chronic inflammation of the digestive tract is associated with aberrant DNA methylation (41, 42) , which frequently coincides with a loss of the Polycomb mark, H3K27me3 (18) . We determined if activation of H3K27me3-marked genes occurs during inflammation and if these activated genes play a role in cancer. We used publically available expression profiles for 15 inflamed mucosal samples from ulcerative colitis (UC) patients, seven unaffected mucosal tissues from UC patients and 13 human colon biopsies from non-inflamed controls obtained from GEO dataset GSE38713 (43) . Analysis of expression profiles for genes with bivalent status in mucosa revealed that almost 20% of bivalent genes already undergo transcriptional changes during inflammation ( Fig.   5A and Table S1 ). Bivalent genes were not activated preferentially over nonbivalent genes (11% versus 10%, respectively). Remarkably, patterns of activation and repression of bivalent genes strongly divided biopsies with and without inflammation (Fig. 5B) . According to Ingenuity pathway analysis, these activated bivalent genes are strongly linked to cancer (Fig. 5C, Fig. S6G ) and are associated with functions associated with cancer development such as cellular movement, cell death and survival, and proliferation (Fig. S6H) and have bivalent status in adjacent mucosa are activated in inflamed tissues from patients with ulcerative colitis (Fig. 5D) . Among these genes, we found FOXQ1, CLDN1, LEF1 and MKI67. However, in contrast to adenoma, expression of stem cell markers including SOX9, LGR5 and ASCL2 was not activated in inflamed tissues. This data provides additional evidence for bivalent gene activation in differentiated mucosa, in the absence of overt tumor formation, and demonstrates that the phenomenon of bivalent promoter activation occurs already during chronic inflammation, a condition strongly correlated with cancer predisposition.
Discussion
Our data suggest that loss of the bivalent (H3K4me3 and H3K27me3) chromatin state at promoters is accompanied by either gain of 5mC (when both marks are lost) or by gene activation (when H3K27me3 is lost) (Fig. 6) . The latter event, as we demonstrate here for the first time, is likely to be a critical step in cancer 
Two non-exclusive models of colorectal cancer initiation have been discussed. According to mouse models, it has been suggested that Lgr5+ cells from the crypt bottom comprise the tumor-initiating cell population (44) . Other models favor a 'top-down' model, in which dysplastic cells can originate in the upper areas of crypts (45, 46) . The latter model invokes a dedifferentiation process in which the cells re-acquire stem cell-like properties. Our data are consistent with a model in which colorectal cancer can arise from differentiated epithelial cells in which the bivalent chromatin state resolves into active or inactive forms. It is likely that the instability of bivalent genes is a mechanism that predisposes the colonic epithelium to cancer by being operative already during inflammatory processes. Elevated NF-țB signaling, as found in chronic inflammation, has been shown to enhance Wnt activation and to induce dedifferentiation of non-stem cells in the colon that acquire tumor-initiating capacity (45) . Inflammation has been linked to methylation of Polycomb-marked genes in the intestinal epithelium of mice (18) . We show here that activation of cancer-relevant genes occurs at bivalent promoters in inflamed differentiated mucosa from ulcerative colitis patients.
Besides inflammation, aging is a major risk factor for cancer. Similar to inflammatory conditions, the aging process has been associated with DNA hypermethylation of Polycomb target genes (47, 48) . If the loss of the Polycomb mark underlies both DNA methylation silencing and the activation of bivalent genes in cancer cells, a mechanistic connection between inflammation, aging and cancer can be proposed, in which gene activation due to H3K27me3 loss may easily be a dominant driving force for the malignant change.
Questions remain as to the possible mechanisms underlying the high variability of the Polycomb mark. Earlier studies showed that the H3K27 methyltransferase EZH2 is downregulated in stressed and senescing populations of cells, which coincided with decreased levels of H3K27me3 at the INK4A-ARF locus (49) . However, it has often been observed that EZH2 is overexpressed in human tumors (50, 51) . In our samples, we observed that EZH2 was expressed at higher levels in tumors than in normal mucosa but we did not find substantial 
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